On March 25, 2026, I attended MAX: Medical Affairs eXcellence Forum, Canada’s first forum dedicated entirely to medical affairs in biopharma. Organized by Agilis Health and held at the Sheraton Toronto Airport, it brought together 140+ professionals spanning Medical Affairs, Pharma, Clinical Research, Regulatory, and Medical Communications for a full day of candid, high-calibre conversation. …
In the first three articles of this series, we looked at AI where people can see it: reading scans and drafting treatment plans, tutoring students and simulating patients, and even helping design the next generation of medicines. But some of the most profound changes are happening out of sight, in the operating system of the …
Traditional drug development is one of the most expensive and failure-prone endeavors in science. Bringing a new drug to market typically takes over a decade, with cost estimates exceeding two billion dollars and failure rates upwards of 90% [1]. Less than 10% of target drugs even make it to Phase I Trials. AI is now …
Continue reading “AI in Healthcare (3): The Molecule Will Design Itself Now—AI in Drug Discovery”
Artificial intelligence is reshaping medicine faster than most health systems can keep up, and few people have a clearer view of that frontier than Dr. Muhammad Mamdani, director of the University of Toronto’s Temerty Centre for AI Research and Education in Medicine (T-CAIREM). On Friday we listened with interest as Dr. Mamdani spoke candidly about …
Rare Disease Day reminds us: “rare” isn’t all that rare. Around 400 million people worldwide—more than cancer and AIDS combined—live with one of over 10,000 rare diseases, 70% of which are genetic and often start in childhood [1,2]. Although definitions vary internationally, Canada generally considers a condition rare when it affects fewer than 1 in …
Continue reading “Bringing Awareness to Rare Disease Day 2026”